Stefania Madonna Selected Research

Biological Products

1/2022	Extracellular Nucleophosmin Is Increased in Psoriasis and Correlates With the Determinants of Cardiovascular Diseases.
8/2018	Eosin treatment for psoriasis reduces skin leukocyte infiltration and secretion of inflammatory chemokines and angiogenic factors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefania Madonna Research Topics

Disease

18	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 03/2006
5	Inflammation (Inflammations) 02/2022 - 03/2011
3	Skin Diseases (Skin Disease) 07/2019 - 07/2013
2	Atopic Dermatitis (Atopic Eczema) 02/2022 - 03/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2021
2	Infections 09/2020 - 07/2007
2	Virus Diseases (Viral Diseases) 09/2020 - 03/2006
2	Neoplasms (Cancer) 07/2017 - 04/2017
1	Dehydration (Water Stress) 02/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2021
1	Arthritis (Polyarthritis) 06/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Overweight 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 09/2020
1	Hidradenitis Suppurativa 01/2020
1	Pathologic Neovascularization 07/2019
1	Skin Abnormalities 12/2017
1	Melanoma (Melanoma, Malignant) 04/2017
1	Wounds and Injuries (Trauma) 11/2015
1	Vascular Diseases (Vascular Disease) 11/2015
1	Ulcer 11/2015
1	Allergic Contact Dermatitis 03/2006
1	Lichen Planus (Lichen Ruber Planus) 03/2006

Drug/Important Bio-Agent (IBA)

8	CytokinesIBA 02/2022 - 07/2007
7	Interleukin-22 (IL-22)IBA 10/2021 - 03/2011
3	ChemokinesIBA 06/2021 - 08/2018
2	Biological ProductsIBA 01/2022 - 08/2018
2	Imiquimod (Aldara)FDA LinkGeneric 10/2021 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2015
2	InterleukinsIBA 01/2021 - 01/2020
2	Messenger RNA (mRNA)IBA 11/2015 - 08/2010
1	AntigensIBA 02/2022
1	Biomarkers (Surrogate Marker)IBA 02/2022
1	Filaggrin ProteinsIBA 02/2022
1	NucleophosminIBA 01/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	seletalisibIBA 10/2021
1	NAD (NADH)IBA 06/2021
1	HLA-C*06 antigenIBA 01/2021
1	secukinumabIBA 01/2021
1	HLA-C Antigens (HLA-C)IBA 01/2021
1	InterferonsIBA 09/2020
1	Antimicrobial PeptidesIBA 09/2020
1	CathelicidinsIBA 09/2020
1	AutoantigensIBA 09/2020
1	DNA (Deoxyribonucleic Acid)IBA 09/2020
1	Insulin-Like Growth Factor Binding Protein 2IBA 01/2020
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	Adalimumab (Humira)FDA Link 01/2020
1	Eosine Yellowish-(YS) (Eosin)IBA 08/2018
1	tofacitinibIBA 01/2018
1	Janus KinasesIBA 01/2018
1	Janus Kinase InhibitorsIBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 12/2017
1	Actin-Related Protein 2-3 Complex (Arp2 3 Complex)IBA 12/2017
1	Interleukin-10 (Interleukin 10)IBA 07/2017
1	Peptides (Polypeptides)IBA 04/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2015
1	Streptozocin (Streptozotocin)FDA Link 11/2015
1	Oxidants (Oxidizing Agents)IBA 01/2014
1	PS 5 (PS-5)IBA 07/2013
1	Sirtuin 1IBA 03/2011
1	Interferon Type IIBA 01/2009
1	beta-DefensinsIBA 07/2007
1	interferon kappaIBA 03/2006
1	Double-Stranded RNA (RNA, Double Stranded)IBA 03/2006

Therapy/Procedure

2	Immunomodulation 01/2020 - 01/2018
1	Therapeutics 01/2020